BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38330859)

  • 1. Variants in the first methionine of RAD51C are homologous recombination proficient due to an alternative start site.
    Rein HL; Bernstein KA
    DNA Repair (Amst); 2024 Mar; 135():103644. PubMed ID: 38330859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous recombination-deficient mutation cluster in tumor suppressor
    Prakash R; Rawal Y; Sullivan MR; Grundy MK; Bret H; Mihalevic MJ; Rein HL; Baird JM; Darrah K; Zhang F; Wang R; Traina TA; Radke MR; Kaufmann SH; Swisher EM; Guérois R; Modesti M; Sung P; Jasin M; Bernstein KA
    Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2202727119. PubMed ID: 36099300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Hu C; Nagaraj AB; Shimelis H; Montalban G; Lee KY; Huang H; Lumby CA; Na J; Susswein LR; Roberts ME; Marshall ML; Hiraki S; LaDuca H; Chao E; Yussuf A; Pesaran T; Neuhausen SL; Haiman CA; Kraft P; Lindstrom S; Palmer JR; Teras LR; Vachon CM; Yao S; Ong I; Nathanson KL; Weitzel JN; Boddicker N; Gnanaolivu R; Polley EC; Mer G; Cui G; Karam R; Richardson ME; Domchek SM; Yadav S; Hruska KS; Dolinsky J; Weroha SJ; Hart SN; Simard J; Masson JY; Pang YP; Couch FJ
    Cancer Res; 2023 Aug; 83(15):2557-2571. PubMed ID: 37253112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
    Clague J; Wilhoite G; Adamson A; Bailis A; Weitzel JN; Neuhausen SL
    PLoS One; 2011; 6(9):e25632. PubMed ID: 21980511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
    Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
    Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
    Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
    Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional analysis of germline RAD51C missense variants highlight the role of RAD51C in replication fork protection.
    Kolinjivadi AM; Chong ST; Choudhary R; Sankar H; Chew EL; Yeo C; Chan SH; Ngeow J
    Hum Mol Genet; 2023 Apr; 32(8):1401-1409. PubMed ID: 36562461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
    Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
    Sullivan MR; Prakash R; Rawal Y; Wang W; Sung P; Radke MR; Kaufmann SH; Swisher EM; Bernstein KA; Jasin M
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
    Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
    Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.
    Li N; McInerny S; Zethoven M; Cheasley D; Lim BWX; Rowley SM; Devereux L; Grewal N; Ahmadloo S; Byrne D; Lee JEA; Li J; Fox SB; John T; Antill Y; Gorringe KL; James PA; Campbell IG
    J Natl Cancer Inst; 2019 Dec; 111(12):1332-1338. PubMed ID: 30949688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decade of RAD51C and RAD51D germline variants in cancer.
    Boni J; Idani A; Roca C; Feliubadaló L; Tomiak E; Weber E; Foulkes WD; Orthwein A; El Haffaf Z; Lazaro C; Rivera B
    Hum Mutat; 2022 Mar; 43(3):285-298. PubMed ID: 34923718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.
    Tumiati M; Munne PM; Edgren H; Eldfors S; Hemmes A; Kuznetsov SG
    Oncogene; 2016 Sep; 35(35):4601-10. PubMed ID: 26820992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Gayarre J; Martín-Gimeno P; Osorio A; Paumard B; Barroso A; Fernández V; de la Hoya M; Rojo A; Caldés T; Palacios J; Urioste M; Benítez J; García MJ
    Br J Cancer; 2017 Sep; 117(7):1048-1062. PubMed ID: 28829762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.
    Dawson LM; Smith KN; Werdyani S; Ndikumana R; Penney C; Wiede LL; Smith KL; Pater JA; MacMillan A; Green J; Drover S; Young TL; O'Rielly DD
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1070. PubMed ID: 31782267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families.
    Osorio A; Endt D; Fernández F; Eirich K; de la Hoya M; Schmutzler R; Caldés T; Meindl A; Schindler D; Benitez J
    Hum Mol Genet; 2012 Jul; 21(13):2889-98. PubMed ID: 22451500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the expression of BRCA2 on spontaneous homologous recombination and DNA damage-induced nuclear foci in Saccharomyces cerevisiae.
    Spugnesi L; Balia C; Collavoli A; Falaschi E; Quercioli V; Caligo MA; Galli A
    Mutagenesis; 2013 Mar; 28(2):187-95. PubMed ID: 23328489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
    Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
    PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
    Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
    Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility.
    Somyajit K; Subramanya S; Nagaraju G
    J Biol Chem; 2012 Jan; 287(5):3366-80. PubMed ID: 22167183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.